ConductScience.org, home

Paper32014348

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.

Shah R and 1 other. Clin Lung Cancer, 2020. Cited by 144 papers, by iCite.

Cite this record

ConductScience Library. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. Papers, record 32014348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32014348

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
PubMed
Journal
Clin Lung Cancer
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
144
iCite
Relative citation ratio, by iCite
6.79
iCite
Revised in PubMed
2021-07-05
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shah RRiyaz
2Lester JFJason F

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
MutationMajor topic
Protein Kinase InhibitorsMajor topic
ErbB Receptors
Humans

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04970693A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by89

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 144 citations.

PMIDTitleJournalYearIn PapersSource
42728535Osimertinib Plus Platinum-Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC.Target Oncol2026https://conductscience.org/library/papers/42728535PubMed
42390540Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.Cancer Chemother Pharmacol2026https://conductscience.org/library/papers/42390540PubMed
42346070MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.Cells2026https://conductscience.org/library/papers/42346070PubMed
42243148The cumulative impact of passenger mutations on cancer development.Nat Commun2026https://conductscience.org/library/papers/42243148PubMed
41851431Inhalable Therapeutics in Lung Cancer: Overcoming Barriers for Effective Treatment.AAPS PharmSciTech2026https://conductscience.org/library/papers/41851431PubMed
41836111The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?Int J Gen Med2026https://conductscience.org/library/papers/41836111PubMed
41821616Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials.Front Pharmacol2026https://conductscience.org/library/papers/41821616PubMed
41759225ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.ESMO Open2026https://conductscience.org/library/papers/41759225PubMed
41683957SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.Int J Mol Sci2026https://conductscience.org/library/papers/41683957PubMed
415120553D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response.Sci Adv2026https://conductscience.org/library/papers/41512055PubMed
41159074Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy - a literature review.RSC Adv2025https://conductscience.org/library/papers/41159074PubMed
41143954EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41143954PubMed
40872484Predicting EGFRL858R/T790M/C797S Inhibitory Effect of Osimertinib Derivatives by Mixed Kernel SVM Enhanced with CLPSO.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40872484PubMed
40483538J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib.Future Oncol2025https://conductscience.org/library/papers/40483538PubMed
40410444*Mechanisms of circular RNA in drug resistance of lung cancer: therapeutic targets, biomarkers, and future research directions.Discov Oncol2025https://conductscience.org/library/papers/40410444PubMed
40365309Ethyl acetate extract of Ruta graveolens: a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC.Front Pharmacol2025https://conductscience.org/library/papers/40365309PubMed
40325239Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs.Med Oncol2025https://conductscience.org/library/papers/40325239PubMed
40280908Engineering aptamer-directed phosphatase recruiting chimeras: a strategy for modulating receptor function and overcoming drug resistance.Nat Commun2025https://conductscience.org/library/papers/40280908PubMed
40259053Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1.Cell Res2025https://conductscience.org/library/papers/40259053PubMed
40255257Investigating the anticancer properties of starter culture of Tripura: an in-silico study on non-small cell lung cancer.In Silico Pharmacol2025https://conductscience.org/library/papers/40255257PubMed

See all 89 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32014348

GET https://conductscience.org/api/papers/v1/32014348/cited_by?page=2